Form 4: Roivant Sciences Director Trades Common Stock

Meghan Fitzgerald, a Director at Roivant Sciences, reported transactions involving the acquisition and disposition of common shares and stock options.

Summary

• Meghan Fitzgerald, a Director at Roivant Sciences, engaged in several transactions on June 30, 2026.
• She acquired 10,000 common shares at a price of $8.80 per share.
• She also disposed of 10,000 common shares at a price of $34.90 per share.
• Following these transactions, Fitzgerald beneficially owns 42,963 common shares directly.
• Additionally, Fitzgerald was awarded 10,000 fully vested stock options to purchase common shares at an exercise price of $8.80, with an expiration date of April 19, 2033. She holds 38,578 derivative securities (stock options) directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine insider transactions without providing new strategic information or significant financial performance indicators.

Positives

• Director Meghan Fitzgerald acquired 10,000 common shares, indicating a potential belief in the company's value.
• The acquisition of shares was at a lower price ($8.80) than the disposition price ($34.90), suggesting a profitable transaction for the director.
• The award of 10,000 fully vested stock options provides potential future upside for the director.

Negatives

• Director Meghan Fitzgerald disposed of 10,000 common shares, which could be interpreted as a reduction in her direct stake or a realization of gains.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported acquisition and disposition of shares by a director are common events, but the significant difference between the acquisition and disposition prices could be of interest to investors.

Stakeholder Impact

• Shareholders may observe director transactions as indicators of confidence or profit-taking, though this filing primarily reflects routine compensation and trading activities.

Key Dates

Keywords

Roivant Sciences, Form 4, Insider Trading, Stock Options, Common Shares, Director Transactions, SEC Filing